Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
All content for On The Pen With Dave Knapp is the property of Bleav, Dave Knapp Founder of On The Pen and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
Eli Lilly Earnings Call Recap: Stock Tanks on Weight Loss Pill Miss
On The Pen With Dave Knapp
59 minutes 23 seconds
2 months ago
Eli Lilly Earnings Call Recap: Stock Tanks on Weight Loss Pill Miss
Zepbound now leads two-thirds of the U.S. obesity market—and that’s just the beginning. In this video, we break down the biggest headlines from Eli Lilly’s latest earnings call, including:
✅ Over 1 million Zepbound vials prescribed in Q2
✅ New Phase 3 tirzepatide trial for type 1 diabetes
✅ 39% reduction in all-cause mortality (MACE-3)
✅ Orforglipron data and pricing strategy revealed
✅ Retatrutide and the future of complex obesity care
✅ Employer coverage shifts and LillyDirect updates
✅ The real reason behind Lilly’s compounding crackdown
✅ How Canadian generics might replace U.S. compounders
🎯 Whether you’re on GLP-1 meds or just trying to get answers in a system that keeps moving the goalposts, this episode is for you.
On The Pen With Dave Knapp
Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
